Comparing Zenas Biopharma (ZBIO) & The Competition

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Zenas Biopharma to related businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Zenas Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Earnings & Valuation

This table compares Zenas Biopharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.23
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-55.29

Zenas Biopharma’s rivals have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Zenas Biopharma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	836	2276	4733	56	2.51

Zenas Biopharma presently has a consensus target price of $40.00, indicating a potential upside of 404.41%. As a group, “Biotechnology” companies have a potential upside of 62.34%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Zenas Biopharma is more favorable than its rivals.

Insider & Institutional Ownership

29.3% of shares of all “Biotechnology” companies are owned by institutional investors. 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.7% and pay out 116.1% of their earnings in the form of a dividend.

Summary

Zenas Biopharma beats its rivals on 7 of the 13 factors compared.

About Zenas Biopharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.